Ironwood Pharmaceuticals
As of the edition of 20 October 2026, Ironwood Pharmaceuticals runs 7 drugs, 2 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 4 |
| Status not established | 1 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Linaclotide | Ends 2029 (exclusivity) | 3 |
| Lesinurad | Ends 2032 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| SLC22A12 Solute carrier family 22 member 12 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Ironwood Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 6 trials led
- Nutrition and metabolism: 1 trials led